Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)Fredrik Schjesvold,Meletios A. Dimopoulos,Sosana Delimpasi,Pawel Robak,Daniel Coriu,Wojciech Maciej Legiec,Ludek Pour,Ivan Spicka,Tamas Masszi,Vadim Anatolievich Doronin,Jiri Minarik,Galina Salogub,Yulia Alexeeva,Antonio Lazzaro,Vladimir Maisnar,Gabor Mikala,Stefan Norin,Marcus Thuresson, Anna Bergan,Jakob Obermuller, Roman Hajek, Maria-Victoria Mateos, Paul G. Richardson, Pieter SonneveldBLOOD（2023）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
